Microsoft, GE receive regulatory clearance for Caradigm joint venture

Microsoft, GE receive regulatory clearance for Caradigm joint venture

Summary: The healthcare joint venture encompasses many of the people and products that were formerly part of Microsoft's Health Services Group.

TOPICS: Health

Microsoft and GE Healthcare received U.S. regulatory approval for their Caradigm joint venture, the pair announced on June 6.

Caradigm (a play on "paradigm" and "care") is a 50-50 joint venture announced in December 2011. The European Commission antitrust authorities gave the new venture the green light on February 13, 2012.

Caradigm is where Microsoft moved almost all of the hundreds people and handful of products that formerly were part of its Health Services Group. (The exception is the HealthVault service and team, which remains part of Microsoft.)

Among the Microsoft technologies Microsoft moved over to Caradigm were the Amalga data aggregation system for hospitals, and the Sentillion healthcare identity-management products. GE is contributing a couple of its healthcare software products to the new venture, as well. Microsoft bought Sentillion in December 2010. Amalga is based on the Azyxxi assets Microsoft bought back in 2006.

Speaking of HealthVault, Microsoft and the AARP announced this week the launch of AARP Health Record, a tool enabling AARP members to enter, store and edit their personal health information in a central location which can be accessed Microsoft's HealthVault service. The free AARP Health Record is available at and

Topic: Health


Mary Jo has covered the tech industry for 30 years for a variety of publications and Web sites, and is a frequent guest on radio, TV and podcasts, speaking about all things Microsoft-related. She is the author of Microsoft 2.0: How Microsoft plans to stay relevant in the post-Gates era (John Wiley & Sons, 2008).

Kick off your day with ZDNet's daily email newsletter. It's the freshest tech news and opinion, served hot. Get it.


Log in or register to start the discussion